Welcome to our dedicated page for Harte Hanks SEC filings (Ticker: HHS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Searching for the numbers behind Harte Hanks’ data-driven marketing engine? Investors typically open the company’s filings to see how cyclical client budgets affect revenue, whether Customer Care margins are expanding, and how logistics costs move the bottom line. Yet a single Harte Hanks annual report 10-K can exceed 250 pages—hardly light reading.
Stock Titan distills every Harte Hanks SEC filing into plain language. Our AI-powered summaries flag segment performance in the 10-K, spotlight cash-flow shifts in the Harte Hanks quarterly earnings report 10-Q filing, and translate 8-K material events explained in minutes. Need to monitor Harte Hanks insider trading Form 4 transactions? Receive real-time alerts the moment a director buys or sells. Curious about the proxy statement executive compensation tables? We highlight pay structures and incentive metrics without the jargon.
Use cases go further: track Harte Hanks executive stock transactions Form 4 to gauge management sentiment; compare marketing-services growth quarter over quarter with our earnings report filing analysis; or get notified when a new contract announcement hits EDGAR so you can act before the market does. Whether you’re understanding Harte Hanks SEC documents with AI or simply want Harte Hanks SEC filings explained simply, Stock Titan delivers every document—10-K, 10-Q, 8-K, Form 4—complete with expert context and historical trends, all updated in real time.
Harte Hanks Inc director Genevieve Combes reported an equity grant of company stock. On 12/09/2025 she was awarded 27,861 restricted stock unit (RSU) shares of common stock at $3.23 per share, scheduled to vest 100% on the first anniversary of the grant date.
After this award, she beneficially owns 26,283 common shares directly, plus 27,861 RSU shares from the 2025 grant, 12,048 RSU shares granted on 5/23/2024 that vested on 5/23/2025, and 16,216 RSU shares granted on 8/17/2023 that vested on 8/17/2024, with receipt of the vested RSU shares deferred until a later date.
Harte Hanks Inc. director Bradley Radoff reported receiving 27,861 shares of common stock as restricted stock units (RSUs) on 12/09/2025 at $3.23 per share. These RSUs will vest 100% on the first anniversary of the grant date.
After this grant, he beneficially owns 27,861 RSUs held indirectly, 391,399 shares of Harte Hanks common stock directly, 20,000 shares held indirectly in an IRA, and 12,048 additional shares held directly that vested 100% on 5/23/2025.
Harte Hanks (HHS) filed its Q3 2025 10‑Q, showing softer demand across all segments and a swing to loss. Revenue was $39.5M (down 17% year over year) with operating income of $0.5M versus $1.9M a year ago. After other expenses of $0.2M and income tax expense of $2.6M, the company reported a net loss of $2.3M (basic and diluted EPS $(0.31)).
By segment in Q3: Marketing Services $8.8M and Customer Care $11.6M declined on customer turnover and program timing, while Fulfillment & Logistics $19.1M delivered stronger profitability, lifting segment operating income to $1.7M from $1.1M last year. Year to date, revenue was $119.7M (down 13.3%) and operating income was $0.5M.
Cash and equivalents were $6.5M at September 30, 2025; net cash used in operating activities was $2.5M year to date. The company extended its $25.0M revolving credit facility to June 30, 2028 at SOFR + 2.25%, had $1.0M in letters of credit outstanding, and no borrowings, leaving $24.0M available capacity. Project Elevate restructuring costs were $0.5M in Q3 and $1.5M year to date; total targeted reorganization savings across 2024–2026 are $16.0M. Shares outstanding were 7,414,794 as of October 31, 2025.
Harte Hanks (HHS)Exhibit 99.1.
The information in Item 2.02, including Exhibit 99.1, is furnished and not deemed filed under the Exchange Act. Harte Hanks’ common stock trades on NASDAQ under the symbol HHS.
Harte Hanks reported lower revenue and a small net loss for the quarter ended June 30, 2025.
Revenue fell to $38.6 million for the quarter (down 14.2% year-over-year) and $80.2 million for the six months (down 11.4%). The company recorded a net loss of $0.3 million for the quarter and $0.7 million for six months, equal to basic and diluted losses per share of $0.05 and $0.10, respectively. Cash and cash equivalents declined to $4.8 million at June 30, 2025. Operating expenses declined year-over-year (11.6% for the quarter; 9.6% for six months) as the company reduced labor and other costs and continued its transformation program, Project Elevate, which targets $16.0 million of cumulative savings. The company extended its asset-based revolving Credit Facility to June 30, 2028 and had $24.0 million of borrowing availability after letters of credit.
FAQ
What is the current stock price of Harte Hanks (HHS)?
What is the market cap of Harte Hanks (HHS)?
